3539 |
Aspirin Plus NOAC Will Be the Standard of Care. |
Roxana Mehran |
Apr. 28. 18 |
3538 |
Micromesh Technology in Carotid Stents: Soft vs. Hard Landing |
Horst Sievert |
Apr. 28. 18 |
3537 |
ERCAO - Carotid Occlusion Recanalization Trial |
Hsien-Li Kao |
Apr. 28. 18 |
3536 |
Aspirin Plus P2Y12 Inhibitor Still Remains as a Key Player. |
Dominick J. Angiolillo |
Apr. 28. 18 |
3535 |
SINE After TEVAR: Predictor and Management |
Young-Guk Ko |
Apr. 28. 18 |
3534 |
Triple vs. Dual Antithrombotic Therapy: Which Regimen & How Long? |
Junya Ako |
Apr. 28. 18 |
3533 |
Coil Embolization for Type II Endoleak After EVAR: Candidates and Outcomes |
Junichi Tazaki |
Apr. 28. 18 |
3532 |
Short- and Long-term EVAR Complications: How to Predict and Prevent |
Jae-Hwan Lee |
Apr. 28. 18 |
3531 |
Ischemic and Bleeding Risk Prediction: Many Scores, Little Solutions |
Tullio Palmerini |
Apr. 28. 18 |
3530 |
Anatomical Consideration for Choosing Different EVAR Devices |
Kishore Sieunarine |
Apr. 28. 18 |